NWPF

News ArchivesRead News

New Drug Eases Psychosis Symptoms in Parkinson's Patients

Monday November 04, 2013

A new drug eases symptoms of psychosis in Parkinson's patients, and it may do the same for those with Alzheimer's
Kristen Fischer

Healthline News - The new drug pimavanserin may help people with Parkinson’s disease experience less severe or frequent symptoms of psychosis.

As of now, the only treatment options for those who experience psychosis—a common symptom for many people with Parkinson's—are dopamine antagonist antipsychotic drugs, such as clozapine and quetiapine. The problem is that they can make motor symptoms worse, accelerate cognitive decline, increase a person’s risk of stroke, and even cause death.

Psychosis is characterized by delusions or hallucinations and is a major reason why people with Parkinson's are often admitted to nursing homes. The new findings offer hope that more patients with Parkinson’s will be able to receive care at home.

Drug Yields Fewer Psychosis Symptoms
Clive Ballard, a professor at King’s College London, lead the research on 199 Parkinson's patients who experienced psychosis and were over the age of 40. Some received 40 mg of pimavanserin once daily; others took a placebo pill.

A nine-item Parkinson's disease scale, known as a SAPS-PD, was used to evaluate their psychosis symptoms throughout the 43-day study.

The researchers found that patients on pimavanserin had better SAPS-PD scores compared to those who took the placebo. Thirty-seven precent of patients taking the drug saw improved scores, compared to just 14 percent of participants on the placebo.

The scientists also noted that patients taking the drug slept better at night, were more wakeful during the day, and were easier for caregivers to treat. And importantly, the patients on pimavanserin did not experience worsening motor symptoms.

How Pimavanserin Works
Pimavanserin blocks serotonin 5-HT2A receptors in the neocortex, the area of the brain that controls sensory perceptions, language, and conscious thought. The neocortex is also linked to visual hallucinations and delusions—both aspects of psychosis.

Among patients taking it, pimavanserin was well tolerated. Researchers said the most common side effect was a slightly elevated risk of urinary tract infections. During the study, 10 patients stopped taking the drug, compared to four on the placebo.

The researchers say that the drug could perhaps be used to treat symptoms of psychosis in those with Alzheimer’s and other dementia-related conditions as well.

Bringing the Drug to Market
How close is pimavanserin to being available for use? Dr. Anne Corbett, co-author of the paper and a psychosis researcher at King’s College, said the U.S. Food and Drug Administration is looking to license the drug. If they approve the medication, it's more likely that the National Institute for Health and Care Excellence in the U.K. will do the same.

She says the drug could have a “considerable” impact on Parkinson’s treatment, giving doctors a valuable option to treat disturbing symptoms.

Pimavanserin is beneficial for caregivers, too, she said. They may not have to put their loved ones in treatment centers, which is often a difficult decision and lifestyle change.

“Since psychosis is often a reason for people moving into residential care, this could mean that people can stay living at home for longer,” Corbett said.

Fischer, K. (4 Nov. 2013). Healthline News. New Drug Eases Psychosis Symptoms in Parkinson's Patients. www.healthline.com.

Recent News

Aug 22 - Parkinson's Disease Could Be Diagnosed Through Eye Check, Mice Help Researchers In Further Study
Aug 22 - Machine learning to unlock Parkinson's disease mystery
Aug 21 - Cognitive control plays major role in Parkinson’s Gait
Aug 15 - 'I've Never Felt Constrained': After Parkinson's Diagnosis, Chestnut Hill Man Turns To Drumming
Aug 11 - Virtual reality and treadmill training could help prevent falls in older adults
Aug 9 - New laboratory model replicates early phase of Parkinson's before onset of motor symptoms
Aug 8 - Marshall University Scientists Develop A New Approach For Parkinson’s Disease Therapy
Aug 5 - Cambuslang woman diagnosed with Parkinson's at 42 is set to trek through Alps
Aug 4 - Active Music Therapy May Be Beneficial in Parkinson's
Aug 1 - Mini-Brains? Scientists Grow Rice Grain-Sized Brains to Aid Parkinson’s Research
Jul 30 - Lab method sheds light on how genetic mutations cause inherited Parkinson's disease
Jul 27 - Indicators of Parkinson's disease risk found in unexpected places
Jul 24 - Parkinson's: Mutant gene interaction may pave the way for new treatments
Jul 22 - Boxing training used to fight against Parkinson's disease
Jul 17 - Stem cell treatment breakthrough could cure Parkinson’s patients
Jul 14 - Cancer drug shows early promise for Parkinson's disease
Jul 13 - Opinion: Dividing the Caregiving Responsibilities Between Siblings
Jul 12 - Researchers make advance in possible treatments for Gaucher, Parkinson’s diseases
Jul 11 - Parkinson’s Head Trauma Link Looks Even Stronger
Jul 7 - Penn students’ start-up XEED puts wearables to work against Parkinson’s disease